Antibe Therapeutics introduces new dental bone graft

Antibe Therapeutics today announced that its subsidiary Citagenix has launched PentOS OI Max for the dental biologics market. PentOS OI Max is the newest member of the PentOS OI family of bone grafts for oral and maxillofacial surgery. PentOS OI Max is an inductive collagen matrix that can be mixed with the clinician’s choice of